某些三唑并噻吩并嘧啶酮类化合物作为抗炎和抗菌剂的合成、评价及建模
Synthesis, evaluation and modeling of some triazolothienopyrimidinones as anti-inflammatory and antimicrobial agents.
作者信息
Bekhit Adnan A, Farghaly Ahmed M, Shafik Ragab M, Elsemary Mona Ma, El-Shoukrofy Mai S, Bekhit Alaa El-Din A, Ibrahim Tamer M
机构信息
Pharmaceutical Chemistry Department, Faculty of Pharmacy, Alexandria University, Alexandria 21521, Egypt.
Food Sciences, University of Otago, Dunedin, New Zealand.
出版信息
Future Med Chem. 2017 Jun;9(9):881-897. doi: 10.4155/fmc-2016-0242. Epub 2017 Jun 21.
AIM
New triazolotetrahydrobenzothienopyrimidinone derivatives were synthesized.
EXPERIMENTAL
Their structures were confirmed, and their anti-inflammatory, antimicrobial activities and ulcerogenic potentials were evaluated.
RESULTS
Compounds 7a, 10a and 11a showed minimal ulcerogenic effect and high selectivity toward human recombinant COX-2 over COX-1 enzyme with IC values of 1.39, 1.22 and 0.56 μM, respectively. Their docking outcome correlated with their biological activity and confirmed the high selectivity binding toward COX-2. Compound 12b displayed antimicrobial activity comparable to that of ampicillin against Escherichia coli while compounds 6 and 11c were similar to ampicillin against Staphylococcus aureus. In addition, compounds 7a, 9a, 10b and 11c showed dual anti-inflammatory/antimicrobial activities.
CONCLUSION
This work represents a promising matrix for developing new potential anti-inflammatory, antimicrobial and dual antimicrobial/anti-inflammatory candidates. [Formula: see text].
目的
合成新型三唑并四氢苯并噻吩并嘧啶酮衍生物。
实验
确认了它们的结构，并评估了它们的抗炎、抗菌活性和致溃疡潜力。
结果
化合物7a、10a和11a显示出最小的致溃疡作用，并且对人重组COX-2相对于COX-1酶具有高选择性，IC值分别为1.39、1.22和0.56 μM。它们的对接结果与其生物活性相关，并证实了对COX-2的高选择性结合。化合物12b对大肠杆菌显示出与氨苄青霉素相当的抗菌活性，而化合物6和11c对金黄色葡萄球菌的抗菌活性与氨苄青霉素相似。此外，化合物7a、9a、10b和11c显示出双重抗炎/抗菌活性。
结论
这项工作为开发新的潜在抗炎、抗菌和双重抗菌/抗炎候选物提供了一个有前景的基础。[公式：见正文]
Zotero 插件